Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC)

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

July 31, 2016

Conditions
Prostate CancerCastration-resistant Prostate Cancer
Interventions
DRUG

Itraconazole

100 mg 200 mg 300 mg

DRUG

Orteronel

300 mg

Trial Locations (3)

20016

Sibley Memorial Hospital, Washington D.C.

21231

Johns Hopkins University, Baltimore

Unknown

Karmanos Cancer Institute, Detroit

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Emmanuel Antonarakis, MD

OTHER